stella
Condition Guide

New Treatments & Clinical Trials for Parkinson's Disease

Last updated August 2026Data from ClinicalTrials.gov621 active trials
← Browse all Parkinson's Disease trials

Parkinson's disease affects around one million Americans, causing tremor, stiffness, and slow movement as dopamine-producing brain cells die off. Current medications replace dopamine or mimic its effects, which helps symptoms but doesn't slow the underlying loss of neurons. Deep brain stimulation can reduce tremor and dyskinesia when medications lose effectiveness.

What's actually going on in research

Trials are testing drugs that might slow or stop neuron loss, including GLP-1 receptor agonists like exenatide, alpha-synuclein antibodies targeting the protein that clumps in Parkinson's, and genetic therapies for people with specific mutations. Researchers are also studying new delivery methods for levodopa, better deep brain stimulation techniques, and treatments for non-motor symptoms like cognitive decline and sleep disorders.

GLP-1 receptor agonists

Diabetes drugs like exenatide and lixisenatide appear to protect brain cells in early studies. Several trials are testing whether these weekly or daily injections can slow Parkinson's progression.

Alpha-synuclein antibodies

These infused drugs target the misfolded protein that accumulates in Parkinson's, similar to how Alzheimer's drugs target amyloid. Early trials are checking whether clearing alpha-synuclein can slow disease progression.

Gene therapies

For people with mutations in GBA1 or LRRK2 genes, trials are testing therapies designed to correct the specific genetic defect. Other gene therapies aim to boost dopamine production or protect remaining neurons.

What to know before you search

Eligibility typically depends on how long you've had Parkinson's, current medications, whether you have a genetic mutation, and scores on movement and cognition tests.

What types of trials are currently open

  • Disease-modifying trials — Testing drugs that might slow neuron loss, usually in people with early Parkinson's. These trials last one to three years and track motor symptoms and brain imaging.
  • Symptomatic trials — Testing new formulations of levodopa, dopamine agonists, or other drugs to control tremor, stiffness, and dyskinesia better than current medications.
  • Device trials — Studies of deep brain stimulation, focused ultrasound, or wearable devices that deliver medication or track symptoms continuously.
  • Non-motor trials — Testing treatments for cognitive problems, depression, constipation, sleep disorders, and other symptoms not helped by dopamine replacement.
  • Genetic studies — Following people with Parkinson's-linked genetic mutations to understand disease progression and test targeted therapies.

Recently added Parkinson's Disease trials

RecruitingInterventional study

Virtual Reality for Motor and Cognitive Function in People With Parkinson's Disease

Parkinson's disease can affect movement, balance, and cognitive function, potentially making daily activities more difficult. This randomized clinical trial aims to investigate whether combining virtual reality with stationary cycling produces different effects on motor and cognitive function compared with stationary cycling alone in people with Parkinson's disease. Participants will be randomly assigned to one of two groups: a control group performing stationary cycling and an intervention group performing stationary cycling while using a virtual reality headset. The intervention will consist of 12 sessions over six weeks, with two sessions per week. Each session will last 40 minutes, including 5 minutes for vital sign assessment before exercise, 30 minutes of cycling, and 5 minutes for vital sign reassessment after exercise. Assessments will be conducted before the intervention, immediately after the six-week program, and at follow-up. The study will examine whether adding virtual reality to stationary cycling may be a useful approach for rehabilitation in people with Parkinson's disease.

Belém, Brazil
RecruitingInterventional study

Expiratory Muscle Strength Training for People With Parkinson's Disease

This study is a Post-Market Clinical Follow-up (PMCF) randomized controlled trial of a CE-marked device used in routine clinical practice. The goal of this study is to investigate whether Expiratory Muscle Strength Training (EMST) improves voice, speech, breathing, and swallowing function in people with Parkinson's disease. The research questions are: Does EMST improve voice, speech, breathing, and swallowing in people with Parkinson's disease, as measured by clinical tests, immediately after the training period and three months later? Does EMST lead to meaningful improvements in voice, speech, breathing, and swallowing problems as reported by people with Parkinson's disease immediately after the training period and three months later? Do the effects of EMST differ according to disease severity? Researchers will compare participants who receive EMST with participants in a passive control group to determine whether EMST improves voice, speech, breathing, and swallowing function. Participants will: Be randomly assigned to either an EMST group or a passive control group. Complete a structured EMST training program, if assigned to the intervention group. Attend study visits for assessments of voice, speech, breathing, and swallowing function. Undergo clinical tests and complete study-related evaluations throughout the study. Be monitored for any device-related or study-related adverse events.

Stockholm, Stockholm County, Sweden
See all recruiting Parkinson's Disease trials →

Find Parkinson's Disease trials matched specifically to you

Answer 3 quick questions and we'll show you trials that fit your situation.

Get matched →